Biogen Gives Up On Gosuranemab After No Benefit Seen In Alzheimer's Study

Phase II TANGO Trial Was Targeting Anti-Tau For Early Disease

 
• By Sten Stovall
TANGO Failure Leaves Debate Open About How, When To Block Tau • Source: Alamy

More from Clinical Trials

More from R&D